Pyrotinib, an oral pan-HER inhibitor, is widely used in patients with HER2-mutated non-small-cell lung cancer and HER2-amplicated breast cancer [36, 37] and displays clinical activity in HER2-positive or HER3-mutated gastric cancer [38, 39]. This evidence concerns the gene ERBB3 and breast cancer.